Earnings Releases·Nov 12, 2026, 6:09 AM ET

MariMed — Third Quarter 2026 Earnings Summary

Consolidated revenue reached $44.2 million for Q3 2026, up 5.5% sequentially and 8.5% year over year, while GAAP net loss widened to $3.5 million from $2.9 million in Q3 2025.
Non-GAAP Adjusted EBITDA declined to $4.7 million in Q3 2026 from $5.1 million in the prior year period, driven by wholesale price compression that reduced non-GAAP gross margin by 140 basis points year over year.
The company reported positive operating cash flow of $6.7 million for the first nine months of 2026 and increased its cash and cash equivalents balance to $10.4 million by quarter-end.
Management intends to leverage its current cash position and production capacity to invest in the business and capture market share in Q4 and beyond, while monitoring federal cannabis reform and 280E tax relief as key industry catalysts.
Strategic highlights include a 150 basis point increase in branded product market share across core markets, the #1 ranking of Betty's Eddies in four core states, and a $0.7 million gain on debt extinguishment during the nine-month period.